China's Licensing Trends Shaping Global Drug Development Analysis Report 2025: Parent Companies Benefitted from Upfront Payments for R&D, Gaining Equity in Novel Chinese Therapeutics [Yahoo! Finance]
Has AstraZeneca's Strong 30% Rally Left Further Upside in 2025? [Yahoo! Finance]
Massive U.S. drug spending gives Trump trade leverage [Globe and Mail, The (Toronto, Canada)]
AstraZeneca advances hematology and cell therapy ambition with largest-ever presence at ASH
Why Astrazeneca (AZN) is a Top Momentum Stock for the Long-Term [Yahoo! Finance]